Basigin mediation of  Plasmodium falciparum red blood cell invasion does not require its transmembrane domain or interaction with monocarboxylate transporter 1.

"a kruskal-wallis comparison followed by dunn's multiple comparison correction was performed to test for differences between groups p < 0 05 was considered statistically significant (tif) click here for additional data file s3 fig a) flow cytometry dot plots illustrating basigin surface expression in bsg ko and rescue populations as assessed by him6 labelling b) flow cytometry histograms illustrating basigin surface expression of successfully rescued populations by comparison to rbc nt ctrl reticulocytes and bsg ko (tif) click here for additional data file s1 data (xlsx) click here for additional data file. file s1 data (xlsx"

"MS is inventor on patents describing the use of RBD ligands and a co-founder and head of the scientific board of METAFORA-Biosystems. AMT is a co-founder, director and consultant to Scarlet Therapeutics Ltd, TJS is a co-founder and scientific consultant to Scarlet Therapeutics Ltd."

"This study was supported through funding provided by the Medical Research Council (MR/V010506/1) to AMT and TJS and the European Union ITN ‘EVIDENCE’ grant agreement ID 860436 and in part by funding from Fondation pour la Recherche Médicale (FRM) grant DBI201312285579 (to MS) and National Institutes of Health (NIH) grant DK32094 (to MS). The funders played no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript."